



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Technically  
Speaking

**CEDARLANE**<sup>®</sup>   
[www.cedarlanelabs.com](http://www.cedarlanelabs.com)

Conveniently Delivering You Today's Innovations  
for the Science of Tomorrow™

### **Anti-Human Calcitonin gene related peptide (CGRP) Polyclonal Antibody**

**CL7792AP**  
**CL7792AP-S**  
**Lot: 189223**

#### **DESCRIPTION:**

Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides, which in humans exists in two forms,  $\alpha$ -CGRP and  $\beta$ -CGRP. CGRP is produced in both peripheral and central neurons and is a potent peptide vasodilator and can function in the transmission of nociception. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role. Increased levels of CGRP have been reported in migraine and temporomandibular joint disorder patients as well as a variety of other diseases such as cardiac failure, hypertension, and sepsis. Several monoclonal antibody therapies targeting CGRP and its receptor have been developed for patients suffering from migraine attacks.

#### **PRESENTATION:**

100  $\mu$ g (**CL7792AP**) or 20  $\mu$ g (**CL7792AP-S**) purified IgG (1 mg/ml) buffered in PBS and 0.02% NaN<sub>3</sub>. (Purified from serum via Affinity Chromatography). For maximum recovery of contents, spin down tube before use.

#### **STORAGE/STABILITY:**

Store at + 4°C. For long term storage, aliquot and freeze unused portion at -20°C in volumes appropriate for single usage. Avoid freeze/thaw cycles.

#### **SPECIFICATION:**

Immunogen: 15 amino acid synthetic peptide located within the human CGRP1 ( $\alpha$ -CGRP) sequence.

Specificity: This antibody is specific for human Calcitonin gene related peptide (CGRP).

IgG Class: Goat IgG

Application: This antibody is suitable for use in ELISA (1:500 – 1:1K) and Immunohistochemistry with paraffin embedded sections (4  $\mu$ g/mL). This antibody has not been tested in other applications.

*Continued....*

Visit our website for your local distributor.

**CEDARLANE**<sup>®</sup> 

[www.cedarlanelabs.com](http://www.cedarlanelabs.com)

An ISO 9001:2015 and ISO 13485:2016  
registered company.

**In CANADA: Toll Free: 1-800-268-5058**

4410 Paletta Court, Burlington, ON L7L 5R2 ph: (289) 288-0001, fax: (289) 288-0020  
e-mail: [general@cedarlanelabs.com](mailto:general@cedarlanelabs.com)

**In the USA: Toll Free: 1-800-721-1644**

1210 Turrentine Street, Burlington, NC 27215 ph: (336) 513-5135, fax: (336) 513-5138  
e-mail: [service@cedarlanelabs.com](mailto:service@cedarlanelabs.com)

## **REFERENCES:**

1. Amara SG, Jonas V, et al. (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. *Nature*. 298 (5871): 240–4.
2. Rosenfeld MG, Mermod JJ, et al (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. *Nature*. 304 (5922): 129–35.
3. Brain SD, Williams TJ, et al. (1985) Calcitonin gene-related peptide is a potent vasodilator. *Nature*. 313(5997): 54–6.
4. Kitamura K. et al. (1992) Isolation and characterization of peptides which act on rat platelets, from a pheochromocytoma. *Biochem. Biophys. Res. Commun.* 185:134-141.
5. Bigal ME, Rapoport AM, et al. (2018). From LBR-101 to Fremanezumab for Migraine. *CNS Drugs*. 32 (11): 1025–1037.

**For Research Use Only**

JK 06/07/19